|
1
|
Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol. 21 (Suppl 5):v1–v100. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, et al: Glioblastoma in adults: A society for neuro-oncology (SNO) and European society of neuro-oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 22:1073–1113. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, et al: The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol. 23:1231–1251. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ostrom QT, Gittleman H, Stetson L, Virk SM and Barnholtzsloan JS: Epidemiology of gliomas. Cancer Treat Res. 163:1–14. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, Fuchs HE, Waite KA, Jemal A, Siegel RL and Barnholtz-Sloan JS: Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 71:381–406. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cini NT, Pennisi M, Genc S, Spandidos DA, Falzone L, Mitsias PD, Tsatsakis A and Taghizadehghalehjoughi A: Glioma lateralization: Focus on the anatomical localization and the distribution of molecular alterations (Review). Oncol Rep. 52:1392024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ellingson B, Lai A, Harris R, Selfridge J, Yong W, Das K, Pope WB, Nghiemphu PL, Vinters HV, Liau LM, et al: Probabilistic radiographic atlas of glioblastoma phenotypes. AJNR Am J Neuroradiol. 34:533–540. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kommers I, Bouget D, Pedersen A, Eijgelaar RS, Ardon H, Barkhof F, Bello L, Berger MS, Conti Nibali M, Furtner J, et al: Glioblastoma surgery imaging-reporting and data system: Standardized reporting of tumor volume, location, and resectability based on automated segmentations. Cancers (Basel). 13:28542021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lapointe S, Perry A and Butowski NA: Primary brain tumours in adults. Lancet. 392:432–446. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stupp R, Hegi ME, Mason WP, Van Den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-Year analysis of the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sinha R, Stephenson JM and Price SJ: A systematic review of cognitive function in patients with glioblastoma undergoing surgery. Neurooncol Pract. 7:131–142. 2020.PubMed/NCBI
|
|
13
|
Kirkman MA, Hunn BH, Thomas MSC and Tolmie AK: Influences on cognitive outcomes in adult patients with gliomas: A systematic review. Front Oncol. 12:9436002022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Genc S, Pennisi M, Yeni Y, Yildirim S, Gattuso G, Altinoz MA, Taghizadehghalehjoughi A, Bolat I, Tsatsakis A, Hacımüftüoğlu A and Falzone L: Potential neurotoxic effects of glioblastoma-derived exosomes in primary cultures of cerebellar neurons via oxidant stress and glutathione depletion. Antioxidants (Basel). 11:12252022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr O, et al: Effect of nivolumab vs. bevacizumab in patients with recurrent glioblastoma: The CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 6:1003–1010. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fukumura D, Kloepper J, Amoozgar Z, Duda DG and Jain RK: Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges. Nat Rev Clin Oncol. 15:325–340. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Khan KA and Kerbel RS: Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol. 15:310–324. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yi M, Jiao D, Qin S, Chu Q, Wu K and Li A: Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 18:602019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang Y, Kim BY, Chan CK, Hahn SM, Weissman IL and Jiang W: Improving immune-vascular crosstalk for cancer immunotherapy. Nat Rev Immunol. 18:195–203. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rahma OE and Hodi FS: The intersection between tumor angiogenesis and immune suppression. Clin Cancer Res. 25:5449–5457. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
De Palma M, Biziato D and Petrova TV: Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 17:457–474. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tate MC and Aghi MK: Biology of angiogenesis and invasion in glioma. Neurotherapeutics. 6:447–457. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Silantyev AS, Falzone L, Libra M, Gurina OI, Kardashova KS, Nikolouzakis TK, Nosyrev AE, Sutton CW, Mitsias PD and Tsatsakis A: Current and future trends on diagnosis and prognosis of glioblastoma: From molecular biology to proteomics. Cells. 8:8632019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hambardzumyan D and Bergers G: Glioblastoma: Defining tumor niches. Trends Cancer. 1:252–265. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xia A, Zhang Y, Xu J, Yin T and Lu XJ: T cell dysfunction in cancer immunity and immunotherapy. Front Immunol. 10:17192019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Barsoum IB, Smallwood CA, Siemens DR and Graham CH: A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 74:665–674. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chon HJ, Lee WS, Yang H, Kong SJ, Lee NK, Moon ES, Choi J, Han EC, Kim JH, Ahn JB, et al: Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune-checkpoint blockade. Clin Cancer Res. 25:1612–1623. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Buckingham SC, Campbell SL, Haas BR, Montana V, Robel S, Ogunrinu T and Sontheimer H: Glutamate release by primary brain tumors induces epileptic activity. Nat Med. 17:1269–1274. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wei Z, Batagov AO, Schinelli S, Wang J, Wang Y, El Fatimy R, Rabinovsky R, Balaj L, Chen CC, Hochberg F, et al: Coding and noncoding landscape of extracellular RNA released by human glioma stem cells. Nat Commun. 8:11452017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ahn JH, Cho H, Kim JH, Kim SH, Ham JS, Park I, Suh SH, Hong SP, Song JH, Hong YK, et al: Meningeal lymphatic vessels at the skull base drain cerebrospinal fluid. Nature. 572:62–66. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mangani D, Weller M and Roth P: The network of immunosuppressive pathways in glioblastoma. Biochem Pharmacol. 130:1–9. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rutledge WC, Kong J, Gao J, Gutman DA, Cooper LAD, Appin C, Park Y, Scarpace L, Mikkelsen T, Cohen ML, et al: Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clin Cancer Res. 19:4951–4960. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber SH, Elsamadicy AA, Cui X, Koyama S, Jackson C, et al: T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma. Clin Cancer Res. 24:4175–4186. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Woroniecka KI, Rhodin KE, Chongsathidkiet P, Keith KA and Fecci PE: T-cell dysfunction in glioblastoma: Applying a new framework. Clin Cancer Res. 24:3792–3802. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, Woroniecka K, Elsamadicy AA, Dechant CA, Kemeny HR, et al: Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med. 24:1459–1468. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hao C, Chen G, Zhao H, Li Y, Chen J, Zhang H, Li S, Zhao Y, Chen F, Li W and Jiang WG: PD-L1 expression in glioblastoma, the clinical and prognostic significance: A systematic literature review and meta-analysis. Front Oncol. 10:10152020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Khasraw M, Walsh KM, Heimberger AB and Ashley DM: What is the burden of proof for tumor mutational burden in gliomas? Neuro Oncol. 23:17–22. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu JB, Bohrson CL, Cortes-Ciriano I, Birzu C, Geduldig JE, Pelton K, et al: Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 580:517–523. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang L, Ge J, Lan Y, Shi Y, Luo Y, Tan Y, Liang M, Deng S, Zhang X, Wang W, et al: Tumor mutational burden is associated with poor outcomes in diffuse glioma. BMC Cancer. 20:2132020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Riviere P, Goodman AM, Okamura R, Barkauskas DA, Whitchurch TJ, Lee S, Khalid N, Collier R, Mareboina M, Frampton GM, et al: High tumor mutational burden correlates with longer survival in immunotherapy-naïve patients with diverse cancers. Mol Cancer Ther. 19:2139–2145. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Oft M: IL-10: Master switch from tumor-promoting inflammation to antitumor immunity. Cancer Immunol Res. 2:194–199. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fontana A, Hengartner H, de Tribolet N and Weber E: Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol. 132:1837–1844. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kumari N, Dwarakanath B, Das A and Bhatt AN: Role of interleukin-6 in cancer progression and therapeutic resistance. Tumor Biol. 37:11553–11572. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kang S, Xie J, Ma S, Liao W, Zhang J and Luo R: Targeted knock down of CCL22 and CCL17 by siRNA during DC differentiation and maturation affects the recruitment of T subsets. Immunobiology. 215:153–162. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Crane CA, Ahn BJ, Han SJ and Parsa AT: Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: Implications for immunotherapy. Neuro Oncol. 14:584–595. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wrann M, Bodmer S, de Martin R, Siepl C, Hofer-Warbinek R, Frei K, Hofer E and Fontana A: T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta. EMBO J. 6:1633–1636. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bryukhovetskiy I and Shevchenko V: Molecular mechanisms of the effect of TGF-β1 on U87 human glioblastoma cells. Oncol Lett. 12:1581–1590. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lohr J, Ratliff T, Huppertz A, Ge Y, Dictus C, Ahmadi R, Grau S, Hiraoka N, Eckstein V, Ecker RC, et al: Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. Clin Cancer Res. 17:4296–4308. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, Herndon JE II, Bigner DD, Dranoff G and Sampson JH: Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 66:3294–3302. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Han S, Liu Y, Li Q, Li Z, Hou H and Wu A: Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma. BMC Cancer. 15:6172015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Schmittnaegel M, Rigamonti N, Kadioglu E, Cassará A, Wyser Rmili C, Kiialainen A, Kienast Y, Mueller HJ, Ooi CH, Laoui D and De Palma M: Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med. 9:eaak96702017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, Feyen K, Tawney J, Hanahan D, Michael IP and Bergers G: Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 9:eaak96792017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A, Kikuchi H, Mamessier E, Aoki S, Ramjiawan RR, et al: Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma. Hepatology. 71:1247–1261. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zheng X, Fang Z, Liu X, Deng S, Zhou P, Wang X, Zhang C, Yin R, Hu H, Chen X, et al: Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. J Clin Invest. 128:2104–2115. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Nayak L, Molinaro AM, Peters K, Clarke JL, Jordan JT, de Groot J, Nghiemphu L, Kaley T, Colman H, McCluskey C, et al: Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma. Clin Cancer Res. 27:1048–1057. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Reardon D, Kaley T, Dietrich J, Clarke J, Dunn G, Lim M, Cloughesy T, Gan H, Park A, Schwarzenberger P, et al: Atim-38. Phase 2 study to evaluate the clinical efficacy and safety of Medi4736 (Durvalumab, Durva)+ bevacizumab (Bev) in Bev-naïve patients with recurrent glioblastoma (Gbm). Neuro Oncol. 20 (Suppl 6):vi102018. View Article : Google Scholar
|
|
57
|
Chamberlain MC and Kim BT: Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: A retrospective case series. J Neurooncol. 133:561–569. 2017. View Article : Google Scholar : PubMed/NCBI
|
